distressing symptom and will help nurses identify patients at risk of developing chronic fatigue after cancer treatment. This information will also aid in patient education, as well as symptom management. C ancer-related fatigue (CRF) is defined as an unusual, persistent, subjective sense of tiredness related to cancer or cancer treatment that interferes with normal functioning and is not relieved by rest or sleep. 1 Cancer-related fatigue, which has a prevalence ranging from 59% to 100%, has been ranked by cancer patients as the longest lasting and most disruptive symptom. 2, 3 A portion of cancer patients who completed therapy continue to experience fatigue more than 1 year after treatment, suggesting a long-lasting effect of cancer and/or cancer treatment. 4, 5 Although the causes of fatigue in cancer patients remain unknown, efforts have been made to understand the underlying mechanisms. It is now widely accepted that infection and inflammation can result in a variety of symptoms including fatigue, lethargy, weakness, anorexia, and anhedonia, collectively termed ''sickness behavior. '' 6 Cytokines are important mediators of sickness behavior; they represent a large family of secreted glycoproteins that act as key mediators in cell signaling and immune response. 7 Upon binding to cytokine receptors, cytokines cause dimerization of the receptors leading to Janus kinase family of tyrosine kinases activation and STAT (signal transducers and activators of transcription) phosphorylation. Phosphorylated STATs dimerize and translocate into the nucleus, where they induce expression of numerous genes including those that are important in immune regulation. 8 There is ample evidence in the existing literature that suggests inflammation plays a role in CRF development. 7, 9 For example, single-nucleotide polymorphisms in the promoter regions of tumor necrosis factor and interleukin 6 (IL-6) were correlated with CRF in breast cancer patients. 10 In another study using plasma samples collected from ovarian cancer patients, IL-6 was correlated with fatigue induced by poor sleep. 11 C-reactive protein was found to be correlated with fatigue in breast cancer survivors. 12 Higher concentrations of IL-6, IL-10, and interferon + (IFN-+) were observed in patients with testicular cancer. 13 Interestingly, activation of the proinflammatory nuclear factor .B transcription pathway appears to be associated with CRF. 14 Despite this abundance of literature showing a possible link between cytokines and fatigue symptoms, 15 the biologic mechanism of persistent fatigue from cancer treatment remains underexplored. This study will specifically focus on the persistent effects of radiation therapy (RT). Radiation therapy is one of the most common therapies for prostate cancer, but there are a number of adverse effects associated with RT including fatigue, as well as urinary, bowel, and sexual dysfunctions. 16 Prostate cancer is a leading cause of death among men in the United States, representing 27% of new cancer cases and 10% of cancer-related deaths. 17 Despite the high rate of deaths, the 5-year survival rate is 99.8% in men with prostate cancer. 17 Current clinical guidelines for treating prostate cancer include active surveillance, radical prostatectomy, and external beam RT (EBRT). 18 Ionizing radiation damages tumors by inducing nuclear DNA breakage and is commonly used in cancer therapy because of its effectiveness. At the same time, radiation is a double-edged sword that gives rise to reactive oxygen species, which in turn induce lipid peroxidation, as well as oxidation of proteins and DNA. 19 Reactive oxygen species generated during RT can trigger inflammatory events and when unchecked induce long-term damage that may result in the symptom of fatigue. 20 It is unclear how peripheral proinflammatory markers triggered by localized radiation induce the intensification or even the persistence of a centrally regulated symptom, such as fatigue. It is worthwhile to investigate if a compromise in the blood-brain barrier (BBB) is associated with the persistence of fatigue following EBRT.
We hypothesize that immunological changes that occur during RT can have long-lasting effects on fatigue. In this study, our objective was to identify early biomarkers that can be detected during RT for persistent fatigue in prostate cancer patients 1 year after completing RT. We want to examine correlations of levels of cytokines during EBRT with the change of fatigue symptom before EBRT to 1 year following treatment completion. The development of peripheral biomarkers detectable during cancer treatment could help clinicians understand the underlying mechanisms of fatigue, evaluate the risk of developing chronic fatigue after treatment, and ultimately help with symptom management and improving patients' quality of life.
n Methods
Participants
The current study (NCT00852111) was approved by the institutional review board of the National Institutes of Health (NIH), Bethesda, Maryland. All participants enrolled in this study were men, 18years or older, received a diagnosis of nonmetastatic prostate cancer with or without prior prostatectomy, and scheduled to receive EBRT with or without concurrent androgen deprivation therapy (ADT). The entire EBRT treatment lasted 38 to 42 days. Potential participants were excluded if they had progressive diseases causing significant fatigue, psychiatric disease within the past 5 years, uncorrected hypothyroidism or anemia, or a second malignancy. Individuals who used sedatives, steroids, or nonsteroidal anti-inflammatory agents were also excluded. Participants were recruited from September 2009 to November 2013 at the Magnuson Clinical Research Center at the NIH, and signed written informed consents were obtained prior to study participation.
were obtained from chart review at baseline (prior to EBRT initiation; T1). Blood cell counts were measured using standard procedures adapted by the Department of Laboratory Medicine, NIH at baseline (T1), midpoint of EBRT (days 19Y21 after EBRT initiation; T2), and 1 year after EBRT (T3).
Fatigue was assessed using the 13-item Functional Assessment of Cancer TherapyYFatigue (FACT-F) questionnaire, which is a frequently used, validated, reliable, stand-alone measure of fatigue in cancer therapy (coefficient ! =.95Y.96). 21 The FACT-F questionnaires were administered by investigators experienced with FACT-F administration in an outpatient setting, before clinical procedures began, in order to avoid extraneous influences on the responses. Each item response was rated on a 0-to 4-point scale, where a 0 represents ''not at all,'' and a 4 indicates that the respondent relates to the corresponding statement ''very much.'' Total scores ranged from 16 to 53, with lower scores reflecting high fatigue intensity. A FACT-F score change of 3 or more is considered clinically significant. 22 High fatigue was defined as a decrease in FACT-F score of 3 or more points from T1 to T3, whereas low-fatigue subjects had a less than 3-point decrease in FACT-F scores between the time points mentioned.
Participants were screened for depression using the validated Hamilton Depression Rating Scale (HAM-D), a 21-item, clinicianrated paper questionnaire with good internal reliability (! =.81Y.98). 23 A score between 0 and 7 indicates normal, whereas scores higher than 8 reflect mild to severe depression. Questionnaires were administered by investigators experienced with HAM-D administration. Both FACT-F and HAM-D were administered at T1, T2, and T3.
Serum Sample Preparation
A total volume of 4mL of whole blood was collected from each subject in a serum separator tube (Becton, Dickinson, and Company, Franklin Lakes, New Jersey) at T1, T2, and T3. Blood samples were centrifuged at 3000revolutions/min for 10minutes at 4-C and collected serum was stored at j80-C prior to analysis.
Cytokine Measurement
To address the purpose of the study to identify early biomarkers of persistent fatigue, a panel of 48 cytokines was measured in 502L of nondiluted serum samples from each participant at T1 and T2 using the Bio-Plex Pro Human Cytokine Kits (BioRad Laboratories, Hercules, California) according to manufacturer's instructions. Briefly, anticytokine conjugated beads were added to each well in a 96-well plate. Following washing with the wash buffer, 502L of standard or undiluted serum sample was added to each well, and the plate was incubated at room temperature for 30minutes. The plates were washed, and 252L of prediluted Bio-Plex detection antibody was added; the plates were then incubated for an additional 30 minutes at room temperature. After 3 washes, 502L of prediluted streptavidinphycoerythrin was added for 10minutes. Following an additional wash, 1252L of Bio-Plex assay buffer was added to each well. Concentrations of the cytokines were quantified using the Luminex 100 instrument.
n Calcitonin Gene Related Peptide Enzyme-Linked Immunosorbent Assay
To ensure that the changes in serum concentrations of proinflammatory cytokines and worsening of fatigue symptoms were not associated with radiation-related disruption in gastrointestinal integrity, 24 serum calcitonin gene related peptide (CGRP) concentrations were measured in all study time points (T1, T2, T3) using the human CGRP enzyme-linked immunosorbent assay (ELISA) kit (MyBioSource, San Diego, California) based on the standard protocol provided by the manufacturer. Briefly, 1002L of standard or undiluted serum was added in duplicates to each well. Following incubation at 37-C for 2hours, the plates were incubated for 1.5hours with 1002L of biotin antibody added to each well. Subsequently, the plates were incubated in the presence of 1002L of horseradish peroxidaseYavidin solution per well for 1hour at 37-C. The plates were washed 5 times and incubated with 902L of TMB (3,3 ¶,5,5 ¶-tetramethylbenzidine) substrate solution added to each well. Absorbance was measured at 450nm on a SpectraMax M3 (Molecular Devices, Sunnyvale, California) plate reader, and CGRP concentrations were calculated based on a standard curve.
n S100B ELISA To determine whether a BBB compromise can explain the association of peripheral expression of cytokines and persistent fatigue, serum samples collected at T1 and T2 were used to measure S100 calcium-binding protein B (S100B) levels, a validated serum marker for BBB disruption, 25, 26 using the human S100B ELISA kit (Millipore, Billerica, Massachusetts) based on the standard protocol provided by the manufacturer. Briefly, 502L of S100B standards (reconstituted from lyophilized S100B) and undiluted serum was added in duplicates to each standard and sample wells in a 96-well plate coated with pretitered human S100B antibodies. Following incubation at room temperature for 2hours, the wells were washed 5 times with TBS/Tween-20. The plates were then incubated for 1.5hours with 1002L of detection antibody added to each well and followed by addition of 1002L of enzyme solution and substrate solution to each well. Absorbance of the reaction product in each well was measured at 450 and 590nm on a SpectraMax M3 (Molecular Devices) plate reader, and S100B concentrations were calculated based on a standard curve generated using a 4-parameter logistic function. The intraassay variations (coefficients of variation) were less than 10%.
Statistical Analysis
Descriptive analyses were used to describe demographic characteristics of the sample. All data are expressed as meanT SEM. Repeated-measures 1-way analysis of variance with post hoc paired t test comparisons were conducted to compare fatigue scores and prostate-specific antigen, CGRP, and S100B levels between time points. Correlation plots and coefficients for the analysis of associations between cytokines and changes in fatigue scores were obtained using MATLAB (MathWorks, Natick, Massachusetts). For each cytokine, Pearson correlation coefficients and P values were calculated by comparing all study participants' T2 cytokine concentrations with all changes in FACT-F scores from T1 to T3. Plots were generated for all significant correlations, omitting single measurements that fell more than 3 SDs from the mean across all participants. The cytokines measured are involved in overlapping signaling pathways; because of this, their measurements should not be treated as independent variables. Hence, the resulting correlations were evaluated 1 biomarker at a time and considered statistically significant at PG .05 without correction for multiple comparisons. A more in-depth assessment of statistical significance is addressed in the Discussion. Cytokines that were found to correlate significantly with changes in fatigue scores were further analyzed using a combination of pathway analysis using Ingenuity Pathway Analysis (Qiagen, Redwood City, California) and literature search using PubMed in order for us to examine the relationships between these cytokines.
n Results
Clinical Characteristics
The study enrolled a total of 52 participants. One participant withdrew from the study because of conflict in schedule, and 18 participants have not completed the T3 study time point. This analysis included a cohort of 34 participants (mean age, 64.3T8.3years) who completed all study time points and received an 8-week regimen of EBRT for localized prostate cancer; 27 participants received a total dosage of 75.6 Gy, and 7 participants with prior prostatectomy received 66.0 to 68.4 Gy ( Table 1) . Prior to EBRT, clinical T2 stage prostate cancer, which indicates that the cancer is localized to the prostate and has not metastasized, was the most prominent diagnosis (61.7%). The average Gleason score of 7.6T0.99 out of 10 suggests that cancer in the majority of participants was moderately aggressive. None of the participants included in the study experienced clinically significant depression symptoms based on the low scores on the HAM-D. Most participants (76.5%) received ADT prior to and during EBRT.
A significant portion of the study cohort (41%) continued to experience high fatigue at T3, which is the focus of this study, whereas FACT-F scores for the rest of the participants went back to baseline levels or higher (Figure 1 ). To rule out common causes of inflammation and fatigue, we compared clinical characteristics of subjects with high fatigue change versus those with low fatigue. The participants with high fatigue at T3 did not differ from the low-fatigue subjects in age (high fatigue: 65.6T1.9; low fatigue: 66.0T 1.9; P=.79), body mass index (high fatigue: 31.5T1.6; low fatigue: 29.0T1.2; P=.13), and concomitant ADT use (high fatigue: 77% of participants; low fatigue: 78% of participants). Furthermore, the prostate-specific antigen levels of all participants remained similar (below 1) at T2 and T3 ( Figure 2A) ; hence, inflammation and fatigue may not be related to recurrence of prostate cancer. In addition, chronic fatigue or inflammation also did not appear to be a result of gastrointestinal involvement from radiation because there was an absence of changes in the concentrations of CGRP, a marker of gastrointestinal integrity, 24 from baseline to midpoint or 1 year after EBRT ( Figure 2B ).
Significant Relationships of T2 Data
We hypothesize that inflammatory response during EBRT contributes to chronic fatigue experience months after treatment completion. In order to identify early biomarkers during treatment that can predict chronic fatigue, we measured a panel of 48 cytokines (listed in Table 2 ) at T2, and the following cytokines were positively correlated with changes in FACT-F score from T1 to T3: (1) Peripheral cytokines can contribute to fatigue either indirectly possibly by activating microglia or directly affecting neural network activity by entering the central nervous system (CNS) through the BBB. 27, 28 To test whether there is a disruption of BBB integrity in prostate cancer patients receiving EBRT that might explain the influence of this peripheral observation with a central behavior such as fatigue, we measured serum concentrations of S100B, which is an established marker for BBB disruption. 25, 26 Serum S100B concentrations did not significantly change over the course of EBRT (Figure 4) . We also did not find a statistically significant correlation between S100B concentrations and FACT-F scores (P9 .05).
We also examined the correlation between fatigue and different blood cell types in order to identify potential contributors to changes in the cytokines that we observed. T2 absolute eosinophil counts and FACT-F scores were negatively correlated (r=j0.42, P=.027; Figure 5A ). Macrophage migration inhibitory factor concentrations, 1 of the 48 cytokines measured, also negatively correlated with FACT-F scores ( Figure 5B ).
n Discussion
In the current study, we demonstrated that 41% of subjects experience chronic fatigue 1 year after EBRT suggesting that chronic fatigue is affecting a large number of men following RT. We observed that immunological changes occurring during EBRT may explain the chronic fatigue experience 1 year after treatment completion. Specifically, we found serum concentrations of 9 cytokines (IL-3, IL-8, IL-9, IL-10, IL-16, IFN-!2, IFN-+, IFN-+Yinduced protein 10 [IP-10], and SDF-1!) measured during EBRT (T2) correlating significantly with worsening fatigue from baseline to 1 year after RT. In contrast, none of these 9 cytokines measured at T1 showed significant correlation with changes in FACT-F score from baseline to 1 year after RT ( Table 2 ), suggesting that the associations of cytokine concentrations and chronic fatigue may be treatment induced and are not preexisting.
The importance of these findings from this pilot study is 3-fold: (1) changes in cytokines during RT may allow us to identify patients at risk of developing chronic fatigue after cancer treatment; (2) immunological dysfunction as evidenced by changes in cytokines during treatment precedes development of chronic fatigue and may help us understand the upstream mechanistic pathways of chronic fatigue; and (3) interventions that modulate cytokine changes during RT may help alleviate chronic fatigue.
The pathway analysis explains the relationships between proinflammatory (IL-3, IL-8, IL-16, IFN-!2, IFN-+) and antiinflammatory (IL-10) cytokines, as well as hematopoietic cytokines (IL-3, IL-9) and chemokines (IP-10 and SDF-1!) with chronic Figure 2 n Fatigue during and after treatment was not related to the health status of study participants. A, Prostate-specific antigen levels significantly decreased at midpoint (T2) of external beam radiation therapy (EBRT) and remained low 1 year after EBRT (T3). B, External beam radiation therapy did not alter calcitonin gene-related peptide (CGRP) concentrations at midpoint (T2) or 1 year after EBRT (T3). Values are expressed as mean T SEM. *P G .05. Figure 1 n Fatigue levels at baseline (T1), at midpoint (T2), and after radiation therapy (T3). Fatigue persisted in 41% (14 of 34) of participants at T3. The Functional Assessment of Cancer TherapyYFatigue (FACT-F) scores of all subjects were greater than 40 at T1, indicating that all subjects were not fatigued prior to radiation therapy. FACT-F scores of study participants in the high-fatigue group and low-fatigue group were comparable at T1 (P = .88) and T2 (P = .67); however, the difference between the 2 fatigue groups became significant at T3 (P =3 Â 10 j6 ). Compared with T1, FACT-F scores in the high fatigue participants decreased at T2 (P = .03) and remained low at T3 (P = .01), indicating both treatment-related fatigue as well as chronic fatigue. Values are expressed as meanT SEM. *P G .05.
fatigue, which are illustrated in Figure 6 . These inflammatory markers are part of a complex interconnected network involving both type 1 and type 2 immunity (Figure 6 ). Interferon +Yinduced protein 10 is secreted by multiple cell types in response to IFN-+ and acts to attract monocytes and macrophages. 29 Similarly, SDF-1! is known to recruit macrophages, as well as contribute to tumor progression. 30 Upon antigen detection, macrophages release IL-8 to attract granulocytes. 31 Secreted by basophils and activated T cells, IL-3 stimulates proliferation of cells of the myeloid lineage including eosinophils. 32 Also known as lymphocyte chemoattractant factor, IL-16 has been shown to attract activated T cells as well as other CD4 + cells including monocytes, dendritic cells, and eosinophils. 33 Our observation of an association between IFN-!2 and fatigue is consistent with previous studies that demonstrated elevated levels of IFN-! in patients with chronic fatigue syndrome. 34 Occupying the central hub of the cytokine network found in our study, IFN-+ in the CNS induces IDO (indoleamine 2,3-dioxygenase) production by monocytes and/or microglia. IDO is the rate-limiting enzyme in the kynurenine pathway, which converts tryptophan into quinolinic acid and/or kynurenine. Because the kynurenine pathway and serotonin (5-HT) production share the same precursor tryptophan, overexpression of IDO is associated with 5-HT depletion, which has both physiological and psychological consequences. 35 Interestingly, quinolinic acid produced in this pathway is an N-methyl-D-aspartate (NMDA) receptor agonist, whereas kynurenine is an NMDA receptor antagonist. As NMDA receptors play an important role in maintaining the balance of CNS excitation and inhibition, it is very likely that disturbances in NMDA activity may have a global effect on the depressive state of the CNS and, consequently, fatigue.
We hypothesize that fatigue is a result of multiple pathogenic processes involving both the peripheral immune system and the CNS. Peripheral immune cells such as eosinophils release a variety of cytokines contributing to peripheral inflammation and leading to peripheral fatigue. In addition, cytokines in the CNS can result in decreased 5-HT production, disruption in long-term potentiation (LTP), and NMDA receptorYinduced excitotoxicity.
35Y39
Our study did not observe any changes in S100B levels over time, suggesting that the radiation received by the study participants did not result in any detectable BBB leakage and that fatigue symptoms were not attributable to cytokines entering the CNS through a compromised BBB. So, how do peripheral cytokines influence symptoms such as chronic fatigue, which is known to be centrally regulated? We propose that changes in cytokines during RT influence CNS physiology via (1) passive diffusion through a BBB via the destruction of tight junctions of endothelial cells lining the BBB microvasculature, (2) entering the brain through existing BBB openingsVcircumventricular organs, (3) retrograde axonal transport, and (4) activating immuneto-brain pathways in the absence of BBB disturbances (ie, peripheral cytokines can induce cytokine production in CNS macrophages and microglia). 40 Indeed, direct effects of cytokines have been observed in the CNS. For example, tumor necrosis factor ! has been shown to inhibit LTP in rat hippocampal slices. 41 Similarly, IL-18 had an inhibitory effect on LTP in the rat dentate gyrus, which was attenuated by application of metabotropic glutamate receptor antagonists. 36 Cytokines can Abbreviations: bNGF, beta-Nerve Growth Factor; CTACK, cutaneous T-cell-attracting chemokine; FGF, fibroblast growth factor; GMCSF, granulocyte-macrophage colony-stimulating factor; GROa, growth-regulated protein alpha; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; IP-10, interferon gamma-induced protein 10; LIF, leukemia inhibitory factor; MCP1, monocyte chemotactic protein 1; MCP3, monocyte chemotactic protein-3; MCSF, macrophage colony-stimulating factor; MIG, monokine induced by interferon-gamma; MIP, macrophage inflammatory protein; PDGF, Platelet-derived growth factor; RANTES, regulated on activation, normal T cell expressed and secreted; SCF, Stem cell factor; SCGFb, stem cell growth factor beta; SDF, stromal cell-derived factor; TRAIL, TNF-related apoptosis-inducing ligand; VEGF, Vascular endothelial growth factor. Bold/italic data indicates significant P values.
induce long-term effects on neuronal networks by affecting synaptic scaling (ie, scaling up of excitatory synapses in response to inactivity and scaling down in response to over-excitation). 42 Central nervous system response to peripheral inflammation results in compensatory changes including alterations in neurotransmitter metabolism and changes in the hypothalamic-pituitaryadrenal axis, both of which can cause changes in behavior including fatigue. 43, 44 Furthermore, chronic peripheral administration of IFN-! reduced striatal dopamine release and anhedonia-like behavior in nonhuman primates. 45 These findings are particularly important because fatigue is associated with impaired motivation and reward-based decision making, which is indicative of a dysfunctional frontostriatal network. 7 It is also worth mentioning that systemic infection as measured by increased serum IL-6 concentrations was correlated with increased cognitive demand on the Stroop task, 46 which is similar to our own observation in fatigued patients (data not shown). The novel correlation between fatigue intensification and eosinophil counts found in this study may be attributable to the increased concentrations of macrophage migration inhibitory factor, which has been shown to induce eosinophil infiltration and activation. 47, 48 Interestingly, eosinophils are a major source of cytokines and have been shown to release up to 35 different cytokines. 49 Consistent with our finding, other groups have shown evidence to suggest a correlation between eosinophils and fatigue symptoms in chronic fatigue syndrome, CRF, and eosinophilia myalgia.
50Y52 However, the mechanism and the exact role of eosinophils in fatigue development remain elusive. It is likely that inflammation induced by radiation results in abnormal immune activation including increased cytokine release from eosinophils. Cytokines can then exert their effects either peripherally through causing muscle function impairment or centrally by affecting NMDA receptor activity and the frontostriatal pathway, which lead to a combination of peripheral and central fatigue.
This study was an initial exploration of the relationship between immune signaling and CRF; as a preliminary study, our sample size was small, limiting our statistical power. We have forgone a multiple-comparisons correction, because the levels of many of the cytokines are regulated by each other or by common upstream signaling molecules. Thus, we would expect to see many rise and fall in tandem, and their measurements should not be treated as independent variables. In fact, this interdependence may be what leads to chronic fatigue correlating with many cytokine measurements taken during treatment (T2, 9 of 43 with PG.05) but only one taken before treatment (T1, one of 44 with PG.05) ( Table 2 ). For comparison, if the measurements were independent and normally distributed, we would expect to see roughly 2 false-positive results for each of T1 and T2. Because there is only a 0.025% chance of seeing this many positive results from a single time point by chance alone, we conclude that our results cross the threshold for considering this a ''statistically significant'' effect. Future study should be conducted with a larger sample size and a restricted list of cytokine measurements to thoroughly address concerns about multiple comparisons.
It is worth noting that while using peripheral biomarkers has the advantage over central markers, because blood samples are easily obtainable, it certainly has the downside that external factors unrelated to the disease state such as sample processing and storage condition can affect cytokine measurements. 53 Furthermore, peripheral cytokine measurements may not reflect levels in the CNS. Future studies should include alternate measures such as cerebrospinal fluid samples to better understand peripheral versus central fatigue.
Using early biomarkers to identify patients who are high risk of developing chronic fatigue a year after EBRT completion has important clinical implications. In the context of individualizing care, this knowledge empowers nurses with the advantage of planning ahead through focused education related to energy conservation or balance in rest and activity. Encouraging physical activity for at-risk individuals, a well-known antiinflammatory strategy, 54 during EBRT that is recommended by national organizations such as the National Comprehensive Cancer Network, 55 can improve treatment outcomes and patients' quality of life. Furthermore, biomarkers found in this study can be easily measured in serum samples using routine, commercially available immunoassay methods including ELISA. Therefore, further validation of these markers using a larger sample would be important to pursue.
In conclusion, prostate cancer patients receiving RT in this study exhibited signs of immunological changes that occurred during EBRT, and these changes correlated significantly with chronic fatigue 1 year after treatment completion. These findings suggest that immunological changes may be upstream in the fatigue pathogenic pathway and that changes in these cytokines may advance our understanding of the biological underpinnings of chronic fatigue related to cancer therapy, so optimal management to improve the lives of cancer patients can be developed.
